Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). (SIRIUS-SLE LTE)
A Randomized, Double-blind, Placebo-controlled Extension Study, Followed by a Study Treatment Withdrawal or Open-label Period, to Assess the Long-term Safety and Tolerability of Ianalumab in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE Extension)
The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The purpose of this extension study is to evaluate long-term safety and tolerability of ianalumab administered s.c. monthly or quarterly, compared to monthly placebo, in adolescent and adult participants with anti-nuclear antibody (ANA)-positive systemic lupus erythematosus of moderate-to-severe disease activity, who have completed either CVAY736F12301 (SIRIUS-SLE 1) or CVAY736F12302 (SIRIUS-SLE 2) core studies.
This extension study will last up to 7 years and includes the following three treatment periods:
- a 3-year double-blind, randomized, placebo-controlled treatment period, evaluating the safety and efficacy of ianalumab or placebo (Period 1);
- followed by a 2-year treatment period evaluating safety and efficacy of treatment withdrawal and open-label ianalumab administered s.c. monthly.
- and an up to 2-year open-label, safety monitoring period (Period 3).
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Expanded Access
Expanded Access
Available
- Available: Expanded access is currently available for this investigational treatment, and patients who are not participants in the clinical study may be able to gain access to the drug, biologic, or medical device being studied.
- No longer available: Expanded access was available for this intervention previously but is not currently available and will not be available in the future.
- Temporarily not available: Expanded access is not currently available for this intervention but is expected to be available in the future.
- Approved for marketing: The intervention has been approved by the U.S. Food and Drug Administration for use by the public.
Contacts and Locations
Study Contact
Study Contact
- Name: Novartis Pharmaceuticals
- Phone Number: 1-888-669-6682
- Email: novartis.email@novartis.com
Study Contact Backup
- Name: Novartis Pharmaceuticals
- Phone Number: +41613241111
- Email: novartis.email@novartis.com
Study Locations
-
-
-
Caba, Argentina, C1015ABO
- Active, not recruiting
- Novartis Investigative Site
-
Caba, Argentina, C1427CCL
- Recruiting
- Novartis Investigative Site
-
San Miguel de Tucumán, Argentina, T4000AXL
- Active, not recruiting
- Novartis Investigative Site
-
-
Buenos Aires
-
La Plata, Buenos Aires, Argentina, B1900AWT
- Recruiting
- Novartis Investigative Site
-
Quilmes, Buenos Aires, Argentina, 1878
- Recruiting
- Novartis Investigative Site
-
San Miguel, Buenos Aires, Argentina, B1663GKT
- Active, not recruiting
- Novartis Investigative Site
-
-
Tucumán Province
-
San Miguel, Tucumán Province, Argentina, T4000CBC
- Active, not recruiting
- Novartis Investigative Site
-
-
-
-
Queensland
-
Maroochydore, Queensland, Australia, 4558
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Salvador, Brazil, 40323-010
- Recruiting
- Novartis Investigative Site
-
-
Espírito Santo
-
Vitória, Espírito Santo, Brazil, 29055-450
- Recruiting
- Novartis Investigative Site
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brazil, 40150-150
- Recruiting
- Novartis Investigative Site
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brazil, 30150-221
- Active, not recruiting
- Novartis Investigative Site
-
-
Paraná
-
Curitiba, Paraná, Brazil, 80030-110
- Recruiting
- Novartis Investigative Site
-
-
Rio de Janeiro
-
Niterói, Rio de Janeiro, Brazil, 24020-096
- Active, not recruiting
- Novartis Investigative Site
-
Rio de Janeiro, Rio de Janeiro, Brazil, 22211-230
- Recruiting
- Novartis Investigative Site
-
-
São Paulo
-
Barretos, São Paulo, Brazil, 14784-400
- Recruiting
- Novartis Investigative Site
-
São Paulo, São Paulo, Brazil, 04038-002
- Active, not recruiting
- Novartis Investigative Site
-
São Paulo, São Paulo, Brazil, 01244-030
- Active, not recruiting
- Novartis Investigative Site
-
-
-
-
-
Sofia, Bulgaria, 1431
- Recruiting
- Novartis Investigative Site
-
-
Bulgaria
-
Plovdiv, Bulgaria, Bulgaria, 4002
- Recruiting
- Novartis Investigative Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1L7
- Active, not recruiting
- Novartis Investigative Site
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 2S8
- Active, not recruiting
- Novartis Investigative Site
-
-
Quebec
-
Rimouski, Quebec, Canada, G5L 5T1
- Recruiting
- Novartis Investigative Site
-
-
-
-
Los Ríos Region
-
Valdivia, Los Ríos Region, Chile, 5110683
- Recruiting
- Novartis Investigative Site
-
-
RM
-
Santiago, RM, Chile, 7500588
- Recruiting
- Novartis Investigative Site
-
-
Santiago Metropolitan
-
Santiago, Santiago Metropolitan, Chile, 7500710
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Beijing, China, 100730
- Recruiting
- Novartis Investigative Site
-
Beijing, China, 100069
- Recruiting
- Novartis Investigative Site
-
Shanghai, China, 200001
- Recruiting
- Novartis Investigative Site
-
Xinxiang, China, 453099
- Recruiting
- Novartis Investigative Site
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Recruiting
- Novartis Investigative Site
-
Guangzhou, Guangdong, China, 510000
- Recruiting
- Novartis Investigative Site
-
Shantou, Guangdong, China, 515000
- Recruiting
- Novartis Investigative Site
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Recruiting
- Novartis Investigative Site
-
Suzhou, Jiangsu, China, 215004
- Recruiting
- Novartis Investigative Site
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- Active, not recruiting
- Novartis Investigative Site
-
Pingxiang, Jiangxi, China, 337000
- Recruiting
- Novartis Investigative Site
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Recruiting
- Novartis Investigative Site
-
-
Shandong
-
Linyi, Shandong, China, 276100
- Recruiting
- Novartis Investigative Site
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recruiting
- Novartis Investigative Site
-
-
Xinjiang
-
Ürümqi, Xinjiang, China, 830001
- Recruiting
- Novartis Investigative Site
-
-
Zhejiang
-
Ningbo, Zhejiang, China, 315016
- Recruiting
- Novartis Investigative Site
-
Wenzhou, Zhejiang, China, 325000
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Bogotá, Colombia, 111211
- Active, not recruiting
- Novartis Investigative Site
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 050001
- Active, not recruiting
- Novartis Investigative Site
-
-
Atlántico
-
Barranquilla, Atlántico, Colombia, 080020
- Active, not recruiting
- Novartis Investigative Site
-
-
Cundinamarca
-
Chía, Cundinamarca, Colombia, 250001
- Active, not recruiting
- Novartis Investigative Site
-
-
Santander Department
-
Bucaramanga, Santander Department, Colombia, 680003
- Active, not recruiting
- Novartis Investigative Site
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombia, 760046
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Brno, Czechia, 638 00
- Recruiting
- Novartis Investigative Site
-
Prague, Czechia, 128 00
- Recruiting
- Novartis Investigative Site
-
Uherské Hradiště, Czechia, 686 01
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Montpellier, France, 34295
- Recruiting
- Novartis Investigative Site
-
Paris, France, 75014
- Active, not recruiting
- Novartis Investigative Site
-
Paris, France, 75013
- Active, not recruiting
- Novartis Investigative Site
-
Toulouse, France, 31059
- Recruiting
- Novartis Investigative Site
-
Toulouse, France, 31054
- Recruiting
- Novartis Investigative Site
-
-
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Germany, 50937
- Withdrawn
- Novartis Investigative Site
-
-
Saxony
-
Leipzig, Saxony, Germany, 04103
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Guatemala City, Guatemala, 01010
- Recruiting
- Novartis Investigative Site
-
-
Departamento de Guatemala
-
Guatemala City, Departamento de Guatemala, Guatemala, 01010
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Budapest, Hungary, 1134
- Recruiting
- Novartis Investigative Site
-
Gyula, Hungary, 5700
- Recruiting
- Novartis Investigative Site
-
Zalaegerszeg, Hungary, 8900
- Recruiting
- Novartis Investigative Site
-
-
Fejér
-
Székesfehérvár, Fejér, Hungary, 8000
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
New Delhi, India, 110075
- Recruiting
- Novartis Investigative Site
-
-
Gujarat
-
Ahmedabad, Gujarat, India, 380015
- Recruiting
- Novartis Investigative Site
-
Ahmedabad, Gujarat, India, 380006
- Recruiting
- Novartis Investigative Site
-
-
Kerala
-
Kozhikode, Kerala, India, 673008
- Recruiting
- Novartis Investigative Site
-
-
Maharashtra
-
Kolhāpur, Maharashtra, India, 416001
- Recruiting
- Novartis Investigative Site
-
Nagpur, Maharashtra, India, 441108
- Recruiting
- Novartis Investigative Site
-
Nashik, Maharashtra, India, 422101
- Recruiting
- Novartis Investigative Site
-
Pune, Maharashtra, India, 411001
- Recruiting
- Novartis Investigative Site
-
Pune, Maharashtra, India, 411007
- Recruiting
- Novartis Investigative Site
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, India, 110060
- Recruiting
- Novartis Investigative Site
-
-
New Delhi
-
New Delhi, New Delhi, India, 110029
- Recruiting
- Novartis Investigative Site
-
-
Uttarakhand
-
Dehradun, Uttarakhand, India, 248001
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Haifa, Israel, 3109601
- Active, not recruiting
- Novartis Investigative Site
-
Ramat Gan, Israel, 5265601
- Recruiting
- Novartis Investigative Site
-
-
-
-
FE
-
Cona, FE, Italy, 44124
- Recruiting
- Novartis Investigative Site
-
-
PD
-
Padova, PD, Italy, 35128
- Recruiting
- Novartis Investigative Site
-
-
PI
-
Pisa, PI, Italy, 56126
- Recruiting
- Novartis Investigative Site
-
-
RM
-
Roma, RM, Italy, 00152
- Recruiting
- Novartis Investigative Site
-
-
TO
-
Torino, TO, Italy, 10128
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Miyazaki, Japan, 8891692
- Recruiting
- Novartis Investigative Site
-
Osaka, Japan, 5458586
- Recruiting
- Novartis Investigative Site
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 4578510
- Active, not recruiting
- Novartis Investigative Site
-
Nagoya, Aichi-ken, Japan, 4578511
- Active, not recruiting
- Novartis Investigative Site
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 0608648
- Active, not recruiting
- Novartis Investigative Site
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan, 2360004
- Active, not recruiting
- Novartis Investigative Site
-
-
Miyagi
-
Sendai, Miyagi, Japan, 9838512
- Recruiting
- Novartis Investigative Site
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan, 1138519
- Recruiting
- Novartis Investigative Site
-
Chuo Ku, Tokyo, Japan, 1048560
- Recruiting
- Novartis Investigative Site
-
Fuchū, Tokyo, Japan, 1838524
- Active, not recruiting
- Novartis Investigative Site
-
Shinjuku-ku, Tokyo, Japan, 1608582
- Active, not recruiting
- Novartis Investigative Site
-
tabashi City, Tokyo, Japan, 1738610
- Active, not recruiting
- Novartis Investigative Site
-
-
-
-
Perak
-
Ipoh, Perak, Malaysia, 30450
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
México, Mexico, 07760
- Active, not recruiting
- Novartis Investigative Site
-
-
Guanajuato
-
León, Guanajuato, Mexico, 37160
- Recruiting
- Novartis Investigative Site
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44160
- Active, not recruiting
- Novartis Investigative Site
-
-
Mexico City
-
Mexico City, Mexico City, Mexico, 06700
- Active, not recruiting
- Novartis Investigative Site
-
-
Michoacán
-
Morelia, Michoacán, Mexico, 58000
- Active, not recruiting
- Novartis Investigative Site
-
-
Yucatán
-
Mérida, Yucatán, Mexico, 97070
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Bydgoszcz, Poland, 85-065
- Recruiting
- Novartis Investigative Site
-
Bydgoszcz, Poland, 85-168
- Recruiting
- Novartis Investigative Site
-
Bytom, Poland, 41 902
- Recruiting
- Novartis Investigative Site
-
Warsaw, Poland, 00-874
- Recruiting
- Novartis Investigative Site
-
Warsaw, Poland, 04-141
- Recruiting
- Novartis Investigative Site
-
-
Lower Silesian Voivodeship
-
Wroclaw, Lower Silesian Voivodeship, Poland, 52-210
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Braga, Portugal, 4710-243
- Recruiting
- Novartis Investigative Site
-
Lisbon, Portugal, 1050-034
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Brasov, Romania, 500283
- Recruiting
- Novartis Investigative Site
-
Bucharest, Romania, 011172
- Recruiting
- Novartis Investigative Site
-
-
Cluj
-
Cluj-Napoca, Cluj, Romania, 400006
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Bratislava, Slovakia, 811 08
- Active, not recruiting
- Novartis Investigative Site
-
Košice, Slovakia, 040 01
- Active, not recruiting
- Novartis Investigative Site
-
-
-
-
-
Umhlanga, South Africa, 4320
- Recruiting
- Novartis Investigative Site
-
-
Gauteng
-
Pretoria, Gauteng, South Africa, 0002
- Recruiting
- Novartis Investigative Site
-
-
Western Cape
-
Cape Town, Western Cape, South Africa, 7500
- Recruiting
- Novartis Investigative Site
-
Cape Town, Western Cape, South Africa, 7405
- Recruiting
- Novartis Investigative Site
-
Somerset West, Western Cape, South Africa, 7130
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Gwangju, South Korea, 61469
- Completed
- Novartis Investigative Site
-
Seoul, South Korea, 06591
- Recruiting
- Novartis Investigative Site
-
Seoul, South Korea, 04763
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Novartis Investigative Site
-
Madrid, Spain, 28034
- Recruiting
- Novartis Investigative Site
-
Valencia, Spain, 46014
- Recruiting
- Novartis Investigative Site
-
-
A Coruna
-
Santiago Compostela, A Coruna, Spain, 15706
- Recruiting
- Novartis Investigative Site
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- Recruiting
- Novartis Investigative Site
-
-
Cantabria
-
Santander, Cantabria, Spain, 39008
- Recruiting
- Novartis Investigative Site
-
-
Catalonia
-
Barcelona, Catalonia, Spain, 08003
- Recruiting
- Novartis Investigative Site
-
-
Madrid
-
San Sebastian Reyes, Madrid, Spain, 28702
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Kaohsiung City, Taiwan, 833
- Recruiting
- Novartis Investigative Site
-
Taichung, Taiwan, 40447
- Recruiting
- Novartis Investigative Site
-
Taichung, Taiwan, 407219
- Recruiting
- Novartis Investigative Site
-
Taipei, Taiwan, 10002
- Recruiting
- Novartis Investigative Site
-
Taipei, Taiwan, 11217
- Recruiting
- Novartis Investigative Site
-
Taoyuan, Taiwan, 33305
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Bangkok, Thailand, 10400
- Recruiting
- Novartis Investigative Site
-
Bangkok, Thailand, 10700
- Recruiting
- Novartis Investigative Site
-
-
Hat Yai
-
Songkhla, Hat Yai, Thailand, 90110
- Recruiting
- Novartis Investigative Site
-
-
Thailand
-
Muang, Thailand, Thailand, 12120
- Recruiting
- Novartis Investigative Site
-
-
-
-
Alabama
-
Anniston, Alabama, United States, 36207
- Recruiting
- Pinnacle Research Group Llc
-
Principal Investigator:
- Vishala L Chindalore
-
Contact:
- Ruby Fields
- Phone Number: +1 256 236 0055
- Email: rfields@pinnacletrials.com
-
-
California
-
Burbank, California, United States, 91505
- Recruiting
- Providence Medical Center
-
Principal Investigator:
- Sue Chung
-
Contact:
- Sandra Figueroa
- Phone Number: +1 818 869 7067
- Email: Sandra.Figueroa@providence.org
-
La Palma, California, United States, 90623
- Recruiting
- Advanced Medical Research
-
Principal Investigator:
- Gerald Ho
-
Contact:
- Reza Azadegan
- Phone Number: +1 714 752 6587
- Email: razadegan@advmedresearch.com
-
Westlake Village, California, United States, 91361
- Active, not recruiting
- Millennium Clinical Trials
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- University of Colorado Denver
-
Principal Investigator:
- Christopher Striebich
-
Contact:
- Chong Pedrick
- Email: chong.pedrick@cuanschutz.edu
-
-
Florida
-
Clearwater, Florida, United States, 33765
- Recruiting
- Clinical Res Of W Florida
-
Principal Investigator:
- Robert Levin
-
Contact:
- Jessica Mayfield
- Phone Number: +1 727 466 0078
- Email: JMayfield@crwf.com
-
Cooper City, Florida, United States, 33024
- Recruiting
- GNP Research
-
Principal Investigator:
- Mark Jaffe
-
Contact:
- Melissa Pierce
- Phone Number: +1 754 248 3589
- Email: melissa@gnpresearch.com
-
Homestead, Florida, United States, 33033
- Recruiting
- Homestead Assoc In Research Inc
-
Principal Investigator:
- Gilberto Seco
-
Contact:
- Mario Hernandez
- Phone Number: 13052460873
- Email: mhernandez@associatesinresearch.com
-
Plantation, Florida, United States, 33324
- Recruiting
- IRIS Research and Development
-
Principal Investigator:
- Guillermo Valenzuela
-
Contact:
- Jhon Galindo
- Phone Number: +1 954 476 2338
- Email: jgalindo@irisrheumatology.com
-
Tampa, Florida, United States, 33603
- Recruiting
- Clinical Research of West Florida Inc
-
Principal Investigator:
- John Carter
-
Contact:
- Abby Carlson
- Phone Number: +1 813 870 1292
- Email: ACarlson@crwf.com
-
-
Georgia
-
Lawrenceville, Georgia, United States, 30044
- Recruiting
- Parris and Associates Rheumatology
-
Principal Investigator:
- Glenn Parris
-
Contact:
- Mannai Coutermarsh
- Phone Number: +17709621616#8334
- Email: m.coutermarsh@parrisandassociates.net
-
-
Illinois
-
Skokie, Illinois, United States, 60076
- Completed
- Robert A Hozman MD SC
-
Willowbrook, Illinois, United States, 60527
- Recruiting
- Willow Rheumatology Wellness
-
Principal Investigator:
- Angela R Crowley
-
Contact:
- Lubna Ali
- Email: lali@willowrheum.com
-
-
Louisiana
-
Lake Charles, Louisiana, United States, 70601
- Recruiting
- Accurate Clinical Research
-
Principal Investigator:
- Enrique Mendez
-
Contact:
- Machell Broussard
- Email: mbroussard@accurateclinicalresearch.com
-
New Orleans, Louisiana, United States, 70112
- Active, not recruiting
- UMC New Orleans
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Active, not recruiting
- University Of Maryland
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Recruiting
- Henry Ford Health
-
Principal Investigator:
- Alireza Meysami
-
Contact:
- Jenna Hudy
- Phone Number: +1 313 916 1984
- Email: jhudy1@hfhs.org
-
Grand Blanc, Michigan, United States, 48439
- Recruiting
- Ahmed Arif Medical Research Center
-
Principal Investigator:
- Ali Karrar
-
Contact:
- Iman Abdelrahman
- Phone Number: +1 810 953 8700
- Email: iman@aamrc.net
-
-
Ohio
-
Middleburg Heights, Ohio, United States, 44130
- Recruiting
- Paramount Med Rsrch and Consult LLC
-
Principal Investigator:
- Isam Diab
-
Contact:
- Denine Ryan
- Phone Number: +1 440 891 9395
- Email: deniner64@gmail.com
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Recruiting
- University Of Pittsburgh
-
Principal Investigator:
- Andreea Coca
-
Contact:
- Kathryn Lemon
- Email: kal128@pitt.edu
-
-
Tennessee
-
Jackson, Tennessee, United States, 38305
- Recruiting
- West Tennessee Research Institute
-
Principal Investigator:
- Jacob A Aelion
-
Contact:
- Rachel Williams
- Phone Number: 17316330119
- Email: rwilliams@arthritisclinic.org
-
Memphis, Tennessee, United States, 38119
- Recruiting
- Shelby Research LLC
-
Principal Investigator:
- Ramesh C Gupta
-
Contact:
- Suvarna Konangula
- Phone Number: +1 901 681 9670
- Email: shelbyres1999@outlook.com
-
-
Texas
-
Bellaire, Texas, United States, 77401
- Recruiting
- Novel Research LLC
-
Principal Investigator:
- Wajeeha Yousaf
-
Contact:
- Hassan Khan
- Email: khan@novelresearch.net
-
League City, Texas, United States, 77573
- Recruiting
- Accurate Clinical Research
-
Principal Investigator:
- Sabeen Najam
-
Contact:
- Mariela Martinez
- Phone Number: +1 281 422 7179
- Email: mmartinez@accurateclinicalresearch.com
-
Red Oak, Texas, United States, 75154
- Recruiting
- Epic Medical Research
-
Principal Investigator:
- Sunny Patel
-
Contact:
- Harshini Potluri
- Phone Number: +1 469 206 2642
- Email: hpotluri@epicmedresearch.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Signed informed consent prior to participation in the extension study. Parent or legal guardian's signed informed consent and child's assent, if appropriate, are required before any assessment is performed for participants <18 years of age. Of note, if the participant reaches age of consent (age as per local law) during the study, they will also need to sign the corresponding study Informed Consent Form (ICF) at the next study visit.
- Participants must have participated in either one of the two SIRIUS-SLE core studies, CVAY736F12301 or CVAY736F12302, and have completed the treatment period through Week 60 without treatment discontinuation.
- In the judgement of the investigator, participants must be expected to clinically benefit from continued study treatment.
Key Exclusion Criteria:
- Use of prohibited therapies.
- Active viral, bacterial or other infections requiring intravenous or intramuscular treatment for clinically significant infection which in the opinion of the investigator will place the participant at risk for participation.
- Plans for administration of live vaccines during the study period.
- Pregnant or nursing (lactating) women.
Other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Ianalumab monthly
Ianalumab s.c. monthly |
Ianalumab s.c. monthly Ianalumab s.c. quarterly
Other Names:
|
|
Experimental: Ianalumab quarterly
Ianalumab s.c. quarterly |
Ianalumab s.c. monthly Ianalumab s.c. quarterly
Other Names:
|
|
Placebo Comparator: Placebo monthly
Placebo s.c. monthly |
Placebo s.c. monthly |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of treatment-emergent Adverse events/Serious Adverse events
Time Frame: through study completion, up to approximately 324 weeks
|
Assessment of long-term safety and tolerability of ianalumab |
through study completion, up to approximately 324 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of participants who achieved Systemic Lupus Erythematosus Responder Index -4 (SRI-4) response
Time Frame: up to Week 324
|
SRI-4 response is defined as:
|
up to Week 324
|
|
Proportion of participants who achieved Definition of Remission in SLE (DORIS) response
Time Frame: up to Week 324
|
DORIS is defined as:
|
up to Week 324
|
|
Change in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index
Time Frame: up to Week 324
|
SLICC/ACR Damage Index is a measure of cumulative damage due to SLE |
up to Week 324
|
|
Average daily dose of corticosteroids administered
Time Frame: up to Week 324
|
Evaluating the effect of ianalumab on corticosteroids intake |
up to Week 324
|
|
Annualized BILAG moderate or severe flare rate
Time Frame: up to Week 324
|
Annualized BILAG moderate or severe flare rate where moderate BILAG flare is defined as 2 or more new BILAG-2004 B items, and severe BILAG flare is defined as 1 or more new BILAG-2004 A items, compared to the previous visit |
up to Week 324
|
|
Ianalumab serum concentrations during treatment and follow-up after last dose
Time Frame: up to Week 324
|
To characterize the Pharmacokinetics (PK) of ianalumab |
up to Week 324
|
|
Incidence and titer of anti-ianalumab antibodies in serum (ADA assay) over time.
Time Frame: up to Week 324
|
To characterize the immunogenicity of ianalumab |
up to Week 324
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CVAY736F12301E1
- 2023-505929-14-00 (Registry Identifier: EU CT NUMBER)
- 2023 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.